Ubs Group Ag Vaxart, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Vaxart, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 825,758 shares of VXRT stock, worth $313,788. This represents 0.0% of its overall portfolio holdings.

Number of Shares

825,758

Previous 559,206 47.67%

Holding current value

$313,788

Previous $229,000 62.01%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.31 - $0.7 $82,631 - $186,586	266,552 Added 47.67%	825,758 $371,000
Q1 2025 May 13, 2025	BUY	$0.41 - $0.94 $25,999 - $59,608	63,413 Added 12.79%	559,206 $229,000
Q4 2024 Feb 14, 2025	BUY	$0.54 - $0.86 $267,556 - $426,108	495,475 Added 155809.75%	495,793 $327,000
Q2 2024 Aug 13, 2024	BUY	$0.53 - $1.3 $168 - $413	318 New	318 $0
Q4 2023 Feb 09, 2024	BUY	$0.57 - $0.85 $23,133 - $34,497	40,585 Added 3399.08%	41,779 $23,000
Q3 2023 Nov 09, 2023	SELL	$0.69 - $0.85 $1,381 - $1,701	-2,002 Reduced 62.64%	1,194 $0
Q2 2023 Aug 11, 2023	SELL	$0.6 - $1.41 $25,044 - $58,853	-41,740 Reduced 92.89%	3,196 $2,000
Q1 2023 May 12, 2023	SELL	$0.71 - $1.25 $2,099 - $3,696	-2,957 Reduced 6.17%	44,936 $34,000
Q4 2022 Feb 08, 2023	BUY	$0.75 - $2.24 $34,232 - $102,240	45,643 Added 2028.58%	47,893 $45,000
Q3 2022 Nov 10, 2022	SELL	$2.09 - $4.5 $49,464 - $106,501	-23,667 Reduced 91.32%	2,250 $5,000
Q2 2022 Aug 10, 2022	SELL	$2.7 - $5.28 $2.19 Million - $4.28 Million	-810,898 Reduced 96.9%	25,917 $91,000
Q1 2022 May 16, 2022	BUY	$4.29 - $6.64 $921,925 - $1.43 Million	214,901 Added 34.55%	836,815 $4.22 Million
Q4 2021 Feb 14, 2022	BUY	$5.77 - $7.96 $1.11 Million - $1.53 Million	191,795 Added 44.59%	621,914 $3.9 Million
Q3 2021 Nov 15, 2021	BUY	$6.67 - $9.8 $2.71 Million - $3.98 Million	405,804 Added 1668.95%	430,119 $3.42 Million
Q2 2021 Aug 13, 2021	SELL	$5.06 - $10.78 $103,471 - $220,440	-20,449 Reduced 45.68%	24,315 $183,000
Q1 2021 May 12, 2021	BUY	$5.64 - $23.33 $209,040 - $864,703	37,064 Added 481.35%	44,764 $271,000
Q4 2020 Feb 11, 2021	SELL	$3.5 - $7.98 $931,896 - $2.12 Million	-266,256 Reduced 97.19%	7,700 $44,000
Q3 2020 Nov 12, 2020	SELL	$4.78 - $16.97 $137,190 - $487,055	-28,701 Reduced 9.48%	273,956 $1.82 Million
Q2 2020 Jul 31, 2020	BUY	$1.68 - $8.85 $486,798 - $2.56 Million	289,761 Added 2246.91%	302,657 $2.68 Million
Q1 2020 May 01, 2020	SELL	$0.34 - $2.87 $16,941 - $143,003	-49,827 Reduced 79.44%	12,896 $23,000
Q4 2019 Feb 14, 2020	SELL	$0.28 - $0.39 $12,565 - $17,501	-44,875 Reduced 41.71%	62,723 $22,000
Q3 2019 Nov 14, 2019	BUY	$0.3 - $0.75 $27,893 - $69,733	92,978 Added 635.96%	107,598 $39,000
Q2 2019 Aug 14, 2019	BUY	$0.63 - $2.04 $6,982 - $22,611	11,084 Added 313.46%	14,620 $10,000
Q1 2019 May 14, 2019	BUY	$1.5 - $2.34 $1,317 - $2,054	878 Added 33.03%	3,536 $7,000
Q4 2018 Feb 14, 2019	SELL	$1.88 - $5.25 $4,805 - $13,419	-2,556 Reduced 49.02%	2,658 $5,000
Q3 2018 Nov 14, 2018	BUY	$2.42 - $3.29 $7,424 - $10,093	3,068 Added 142.96%	5,214 $15,000
Q2 2018 Aug 14, 2018	BUY	$2.88 - $6.0 $6,180 - $12,876	2,146 New	2,146 $7,000

Others Institutions Holding VXRT

# of Institutions

105

Shares Held

23.1M

Call Options Held

50.3K

Put Options Held

View Full List

About Vaxart, Inc.

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $48.1M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

More about VXRT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account